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Introduction. Wiskott-Aldrich syndrome is a rare X-linked disorder characterized by micro-
thrombocytopenia, eczema, and recurrent infections. It is caused by mutations of the WAS 
gene which encodes the WAS protein (WASp) – a key regulator of actin polymerization in 
hematopoietic cells. Mutations within the WASp gene result in a wide heterogeneity of clini-
cal disease, ranging from ‘classical WAS’ to mild asymptomatic thrombocytopenia (X-linked 
thrombocytopenia [XLT]), or congenital neutropenia (X-lined neutropenia [XLN]). 
Case presentation. This present paper reports a phenotypical and laboratory description of 
two children diagnosed with WAS and one child diagnosed with XLT. The first case was a six 
months old male with septicemia, thrombocytopenia, eczema and petechial rash. The second 
case was a 2 years old boy presenting with complaints of recurrent infections, eczema and 
thrombocytopenia with small platelet size. The third case was a 16 years old boy who pre-
sented with thrombocytopenia and recurrent sinopulmonary infections. 
Conclusions. Due to a wide spectrum of clinical findings, the diagnosis of WAS/XLT should 
be considered in any male patient presenting with petechiae, bruises, and congenital or 


























ANALIZA CARACTERISTICILOR CLINICE ȘI MOLECULAR-GENETICE ALE 
SINDROMULUI WISKOTT-ALDRICH ȘI TROMBOCITOPENIA X-LINKATĂ  
Introducere. Sindromul Wiskott-Aldrich este o afecțiune rară X-linkată, caracterizată prin 
microtrombocitopenie, eczeme și infecții recurente. Acesta este cauzat de mutații ale genei 
WAS, care codifică proteina WAS (WASp) - un regulator cheie al polimerizării actinei în 
celulele hematopoietice. Mutațiile din gena WASp generează o eterogenitate largă a bolii 
clinice, variind de la „WAS clasic” la trombocitopenie asimptomatică ușoară (trombocitope-
nie X-linkată [XLT]) sau la neutropenie congenitală (neutropenie X-linkată [XLN]). 
Prezentarea cazului. Este raportată descrierea, fenotipică și de laborator, a doi copii diag-
nosticați cu WAS și a unui copil diagnosticat cu XLT. În primul caz, un băiat în vârstă de șase 
luni, cu septicemie, trombocitopenie, eczemă și erupții de tip peteșii. În al doilea caz, un băiat 
de 2 ani, care a prezentat acuze de infecții recurente, eczemă și trombocitopenie, cu dimen-
siune mică a trombocitelor. Iar în al treilea caz, un băiat de 16 ani, care s-a adresat cu acuze 
de infecții sinopulmonare recurente și trombocitopenie. 
Concluzii. Datorită spectrului larg de manifestări clinice, diagnosticul WAS/XLT trebuie luat 
în considerare la orice pacient de sex masculin, care prezintă erupții de tip peteșii, echimoze 
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The Wiskott-Aldrich syndrome (WAS, OMIM 
301000) is a rare X-linked immunodeficiency 
syndrome originally described by Dr. Alfred Wis-
kott in 1937 and Dr. Robert Aldrich in 1954 as a 
familial disease, characterized by the classic triad 
of severe immunodeficiency, microthrombocyto-
penia, and eczema. The incidence of WAS is esti-
mated at between 1 in 105 and 1 in 106 cases per 
live birth and WAS makes up approximately 3% 
of all Primary Immunodeficiencies Disorders in 
the European Society for Immunodeficiency reg-
istry (1). 
The gene responsible for WAS is located on the 
short arm of the X chromosome at Xp11.22–
p11.23. The WAS gene encodes the WAS protein 
(WASp), which is a cytosolic multidomain 502-
amino acid protein expressed within the cyto-
plasm of nonerythroid hematopoietic cells. WASp 
is involved in actin polymerization and associated 
coupling of receptor engagement, signaling 
events, and cytoskeletal rearrangement (2). Mu-
tations within the WASp gene result in a wide het-
erogeneity of clinical disease, ranging from ‘clas-
sical WAS’, where babies present in the first year 
of life with a severe persistent thrombo-cytope-
nia, opportunistic and increased frequency of res-
piratory tract infections and early development of 
autoimmunity (3), to mild asymptomatic throm-
bocytopenia (X-linked thrombocytopenia [XLT]), 
or congenital neutropenia (X-lined neutropenia 
[XLN]) (1). X-linked thrombocytopenia (XLT), 
shares similar bleeding risk from thrombocytope-
nia but is not associated with other significant 
clinical features and is generally managed conser-
vatively (4). 
In WASP-deficient cells, the formation of the Im-
munological Synapse (IS) in T cells and T Cell Re-
ceptor (TCR)-dependent activation, the cyto-toxic 
activity of CD8+ T cells and Natural Killer (NK) 
cells and the suppressor activity of Naturally oc-
curring Regulatory T (nTreg) cells are all im-
paired. Motility, adhesion and migration of B cells 
are also defective. Additionally, the lack of WASP 
affects podosome formation, motility and T cell 
priming in Dendritic Cells, as well as podosome 
and phagocytic cup formation in macrophages 
(5). 
Low number of platelets and thrombocytopenia 
are universal features of WAS, usually present in 
the   first  year  of   life  and  typically  causing pete- 
chiae, easy bruising, spontaneous or prolonged 
bleeding. Life-threatening bleeding episodes, par-
ticularly gastrointestinal or intracranial blee-
ding, have been reported in 10–30% of patients 
(4). Patients with WAS are at a higher risk of de-
veloping autoimmunity, the most frequent being 
hemolytic anemia (36%), followed by vasculitis 
(including cerebral vasculitis; 29%), arthritis 
(29%), neutropenia (25%), inflamma-tory bowel 
disease (9%), and IgA nephropathy (3%). 
Henoch–Schönlein-like purpura, dermatomyo-
sitis, recurrent angioedema, and uveitis have also 
been reported in some patients (5). Furthermore, 
WAS patients often develop hematological malig-
nancies often associated with Epstein-Barr virus 
infection and of poor prognosis (6). The tumor in-
cidence in WAS is estimated to be 13–22% with a 
mean age of onset of 9.5 years and with poor 
prognosis. WAS patient tumors include non-
Hodgkin lymphoma, EBV positive and EBV nega-
tive lymphoma, Hodgkin lymphoma, Burkitt lym-
phoma, and less frequently myelodysplasia, acute 
lymphoblastic leukemia, myelomonocytic leuke-
mia, and nonhematopoietic malignancies (7, 8). 
The immunodeficiency in WAS involves T cells, 
and is associated with both quantitative and qual-
itative defects in T cells. Humoral immune re-
sponses are abnormal: patients with WAS exhibit 
variable levels of serum IgM, normal to high levels 
of serum IgA, and high levels of serum IgD, IgG, 
and IgE (2). Despite the presence of normal num-
bers of neutrophils, monocytes, and other phago-
cytes, functional abnormalities may also be pre-
sent in patients with WAS. Chemotaxis, the initia-
tion of degranulation, the formation of a func-
tional respiratory burst, and antibody-medi-ated 
phagocytosis may be impaired in patients with 
WAS (9). 
With regard to treatment, hematopoietic stem cell 
transplantation (HSCT) is the current accepted 
curative approach for patients with WAS. Patients 
with WAS, who undergo unrelated donor HSCT at 
younger ages (less than 5 years of age), have out-
comes that are comparable to those associated 
with the use of matched-sibling donor HSCT (3). 
At present, gene therapy in WAS patients offers 
remarkable possibilities. The first gene therapy 
study in WAS used a γ-retroviral vector, with 
WASp expression driven via the viral promoter 
(10). Restoration of T proliferative responses, 
polyclonal T-cell repertoires, natural killer cell cy-
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were demonstrated post treatment, and platelet 
counts were either within the normal range 
(43%) or significantly higher than pregene ther-
apy (57%) (11). Another trial used a self-inacti-
vating lentivirus vector for WAS gene correction 
in which a 1.6 kb fragment of the proximal pro-
moter of the WAS gene is used to express the full-
length coding sequence of the human WAS gene in 
cells of the hematopoietic lineage. Consequently, 
there has been an improvement at 24 months in 
eczema, the frequency and severity of infections, 
bleeding tendency, autoimmunity, reduction in 
disease-related days of hospitalization and im-
provement in immunological and haematological 
parameters (12, 13). This vector has also been ap-
plied to adult WAS patient (14). 
 
CASE PRESENTATION 
Patients were referred to the Human Molecular 
Genetics Laboratory at the Institute of Mother 
and Child, for genetic counselling. In order to es-
tablish the diagnosis, the WAS clinical scoring sys-
tem was used, which ranges between 0 and 5, in-
cluding the presence of thrombocytopenia, ec-
zema, immunodeficiency, autoimmunity, and ma-
lignancy. Immunological investigations were per-
formed in order to identify changes suggestive of 
the presence of the disease in suspected patients. 
The number of T-cell receptor excision circle 
(TREC)/kappa-deleting recombination excision 
circle (KREC) copies were quantified by qPCR and 
were related to the albumin control gene. 
The first case was a 6-month-old male patient 
with a WAS score equal to 3 which is considered 
“classic” WAS. He was the first child born from 
nonconsanguineous parents. He was admitted to 
the IMSP Institute of Mother and Child with septi-
cemia, thrombocytopenia, eczema and petechial 
rash. The patient also presented with restraint in 
physical development (petty malnutrition) and 
motor-hypotonicity. Besides those mentioned 
above, the patient also revealed respiratory insuf-
ficiency, cytomegalovirus hepatitis, signs of car-
dio-circulatory insufficiency, disseminated intra-
vascular coagulation. During the hospitalization, 
the condition of the child was severe, presenting 
cardio-circulatory insufficiency, marked hepato-
megaly, myotonia, and psychomotor retardation. 
Quantitative serum immunoglobulin tests de-
tected a low serum level of IgM (0.3 g/L) and IgA 
(0.2 g/L), elevated  IgE (767.6 kU/L), low  level  of  
CD4(+) T cells (9%), elevated CD8(+) T cells 
(59%). Treatment is directed mainly at control of 
bleeding through transfusions of blood and plate-
lets, and control of infections with antibiotics and 
Immunoglobulin replacement. 
The second case was a 2-year-old boy presenting 
with complaints of recurrent infections, eczema 
and thrombocytopenia with small platelet size 
(WAS clinical score – 3). The mother of the patient 
had a brother who died at a young age and no 
clear diagnosis was made at that time. Analysis of 
serum immunoglobulins revealed a low serum 
level of IgM (0.2 g/L), normal IgA (1.39 g/L) and 
normal IgG (7.18 g/L), low level of CD3(+) (63%), 
low level of CD4(+) T cells (32%), elevated 
CD8(+) T cells (28%), elevated CD16(+) (32%). 
Quantification of TREC/KREC copies showed low 
TREC and KREC levels.  
The third case was a 16-year-old boy who pre-
sented with thrombocytopenia and recurrent si-
nopulmonary infections. In the present case, the 
WAS clinical score was 2, which rather suggested 
the presence of XLT. Immunological investiga-
tions indicated a normal immunoglobulin profile, 
low level of CD4(+) T cells (29,8%) and elevated 
CD8(+) T cells (36,6%). TREC and KREC copy 
counts revealed low TREC levels while KREC level 
was within the normal range.  
 
DISCUSSIONS 
During the period 2016-2020, WAS was clinically 
suspected in 5 patients, all of Caucasian ethnicity. 
The diagnosis was genetically confirmed in 3 pa-
tients.  
Diagnosing Wiskott-Aldrich syndrome can be dif-
ficult and is often overlooked or confused with 
other more common conditions. The presence of 
family history makes the diagnosis easier. The 
mean age at the time of diagnosis is 24 months in 
patients whose family members are unaffected by 
this syndrome previously (15).  
For the purpose of performing the genetic test, ge-
nomic DNA was isolated from peripheral blood 
leukocytes by using the Salting-out method. In or-
der to examine mutations on the WAS gene, direct 
sequencing was performed on the ABI 3500 DX 
Genetic Analyzer (Applied Biosystems) for all 12 
coding regions of the WAS gene listed in Table 1. 
Data were analyzed using the bioinformatic soft-
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Forward  TTAACCAGACAGGAAGCAAT 593 
Reverse CTTGAGTGAAGAGAACTGAGA 
 
Genetic analysis of WAS gene was performed in 
the first patient, and subsequently in the patient’s 
mother. The direct sequencing analysis showed 
A-to-G transition at complementary nucleotide 
274 (c.274-2 A>G), located in intron 2 (fig. 1a). 
Molecular analysis of the WAS gene performed in 
the patient’s mother revealed no mutation. Thus, 
taking into consideration that family history anal-
ysis did not reveal the presence of relatives with 
clinical features of Wiskott-Aldrich syndrome, 
and DNA analysis of the patient's mother did not 
disclose any mutation, we could assume that the 
mutation found in the patient appeared de novo. 
The severe phenotype of the patient correlated 
with the presence of an aberrant protein.  
In the second case, genetic analysis for the detec-
tion of a mutation of WAS gene showed a patho-
genic mutation – c.391 G>A (p. E131K) in exon 3 
(fig. 1b). Direct sequencing performed in the 
patient’s mother confirmed that she is a heterozy-
gous carrier of the same mutation. Family history 
analysis revealed the presence of a family mem-
ber (the maternal uncle) with clinical signs simi-
lar to Wiskott Aldrich syndrome, who died in 
childhood. 
In the third case, molecular genetic analysis per-
formed through Sanger sequencing of the WAS 
gene revealed two mutations – c.57 G>T (p. 
Q19H) in the first exon, and c.136 C>A (p. L46M) 
in the second exon (fig. 1c). The presumed impact 
on the patient phenotype was investigated on The 
Ensembl Variant Effect Predictor and as a result, 
c.57 G>T (p. Q19H) mutation had a severe pheno-
typic effect, while the impact of c.136 C>A (p. 
L46M) mutation was moderate. Considering the 
patient's age, the WAS clinical score, the immuno-
logical picture and the data of the molecular ge-
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Figure 1. Sequencing identification of mutations in the WAS gene. Wave overlay denotes the pres-
ence of the mutation in labeled nucleotide. 
a. Mutation c.274-2 A>G located in intron 2 of WAS gene in the first case 
b. Mutation c.391 G>A located in exon 3 of WAS gene in the second case 
c. Mutation c.57 G>T located in exon 1 of WAS gene in the third case 
d. Mutation c.136 C>A in exon 3 of WAS gene in the third case 
 
CONCLUSIONS  
1. Due to a wide spectrum of clinical findings, the diagnosis of WAS/XLT should be considered in any 
male patient presenting with petechiae, bruises, and congenital or early-onset thrombocytopenia 
associated with small platelet size.  
2. Obtaining a definitive and specific molecular diagnosis for a patient with clinically suspected Wis-
kott-Aldrich syndrome is important because it ensures more effective medical management, al-
lows early access to standard care, avoiding invasive investigations and significant impact  on the 
evolution of the disease. 
 
CONFLICT OF INTERESTS 




1. Worth AJ, Thrasher AJ. Current and emerging 
treatment options for Wiskott-Aldrich syn-
drome. Expert Review of Clinical Immunology. 
2015;11(9):1015-32. 
2. Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich 
syndrome: A comprehensive review. Ann N Y 
Acad Sci. 2013;1285:26-43. 
3. Mahlaoui N, Pellier I, Mignot C, Jais JP, Bilhou-Na-
béra C, et al. Chacteristics and outcome of early-
onset, severe forms of Wiskott-Aldrich syndrome. 
Blood. 2013;121(9):1510-6. 
4. Rivers E, Worth A, Thrasher AJ, Burns SO. How I 
manage patients with Wiskott Aldrich syndrome. 
Br J Haematol. 2019;185(4):647-655. 
5. Catucci M, Castiello MC, Pala F, Bosticardo M, Villa 
A. Autoimmunity in wiskott-Aldrich syndrome: 
an unsolved enigma. Front Immunol. 2012;3:209. 
6. Mortaz  E,  Tabarsi   P,   Mansouri   D,   Khosravi A,  
Garssen J, et al. Cancers Related to Immunodefi-
ciencies: Update and Perspectives. Front Immu-
nol. 2016;7:365.  
7. Yoshimi A, Kamachi Y, Imai K, Watanabe N, Naka-
date H, et al. Wiskott-Aldrich syndrome present-
ing with a clinical picture mimicking juvenile my-
elomonocytic leukaemia. Pediatr Blood Cancer. 
2013;60(5):836-41. 
8. Du S, Scuderi R, Malicki DM, Willert J, Bastian J, et 
al. Hodgkin's and non-Hodgkin's lymphomas oc-
curring in two brothers with Wiskott-Aldrich syn-
drome and review of the literature. Pediatr Dev 
Pathol. 2011;14(1):64-70. 
9. Kumar S, Xu J, Perkins C, Guo F, Snapper S, et al. 
Cdc42 regulates neutrophil migration via cross-
talk between WASp, CD11b, and microtubules. 
Blood. 2012;120(17):3563-3574.  
10. Boztug K, Dewey RA, Klein C. Development of 




   66  
 
VOL. 2, ISSUE 3 
2021 
 
Wiskott-Aldrich syndrome. Current Opinion in 
Molecular Therapeutics. 2006;8(5):390-5. 
11. Braun CJ, Boztug K, Paruzynski A, Witzel M, 
Schwarzer A, et al. Gene therapy for Wiskott-Al-
drich syndrome-long-term efficacy and genotox-
icity. Sci Transl Med. 2014;6(227): 227ra33. 
12. Hacein-Bey Abina S, Gaspar HB, Blondeau J, Cac-
cavelli L, Charrier S, et al. Outcomes following 
gene therapy in patients with severe Wiskott-Al-
drich syndrome. JAMA. 2015;313(15):1550-63. 
13. Chu J, Henderson L, Lauren A, Myriam M, Frances 
D. Gene Therapy Using a Self-Inactivating Lenti-
viral Vector Improves Clinical and Laboratory 
Manifestations of Wiskott-Aldrich Syndrome. 
Blood. 2015;126:260-260. 
14. Morris EC, Fox T, Chakraverty R, Tendeiro R, 
Snell K, et al. Gene therapy for Wiskott-Aldrich 
syndrome in a severely affected adult. Blood. 
2017;130(11):1327-1335. 
15. Buchbinder D, Nugent DJ, Fillipovich AH. Wis-
kott-Aldrich syndrome: diagnosis, current man-
agement, and emerging treatments. Appl Clin 
Genet. 2014;7:55-66. 
16. Park SK, Kim CS, Song DK, Kim JY, Choi IJ, et al. A 
familial case of Wiskott-Aldrich Syndrome with a 
hotspot mutation in exon 2 of the WAS Gene. J Ko-
rean Med Sci. 2007;22(6):998-1001. 
17. Jones LN, Lutskiy MI, Cooley J, Kenney DM, Rosen 
FS, et al. A novel protocol to identify mutations in 
patients with wiskott-Aldrich syndrome. Blood 
Cells Mol Dis. 2002;28(3):392-8. 
18. He X, Zou R, Zhang B, You Y, Yang Y, et al. Whole 
Wiskott-Aldrich syndrome protein gene deletion 
identified by high throughput sequencing. Mol 
Med Rep. 2017;16(5):6526-6531. 
 
Date of receipt of the manuscript: 29/01/2021 
Date of acceptance for publication: 03/06/2021 
 
Doina TURCAN, ORCID ID: 0000-0002-8571-0524 
Lucia ANDRIES, ORCID ID: 0000-0002-3155-0422 
Alexandr DORIF, ORCID ID: 0000-0003-4269-4066 
Victoria SACARA, ORCID ID: 0000-0001-9200-0494 
